Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 10/20 | 0.69 |
| ▸ | GNAI1 | P63096 | 10/20 | 0.69 |
| ▸ | GNAO1 | P09471 | 9/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | NAAA | Q02083 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9120685 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL6536788 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL9658815 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL18651303 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL6488462 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL3601270 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL23533349 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL8973027 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL8972999 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 | |
| SCHEMBL8973060 | 1.00 | GNAI3 (0.69) | GNAI3GNAI1GNAO1L3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102898377-A | Novel phthalazinone derivatives and uses thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2013-01-30 | — | — | CN | claimed |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| CN-102898377-B | One class phthalazinone derivatives and uses thereof | NANJING SANHOME PHARMACEUTICAL CO., LTD. (CN) | 2016-01-20 | — | — | CN | disclosed |
| CN-102898377-A | Novel phthalazinone derivatives and uses thereof | NANJING SANHOME PHARMACEUTICAL CO LTD | 2013-01-30 | — | — | CN | disclosed |
| EP-0582065-A1 | 1-Oxohydrocarbyl-substituted azacyclohexanes compositions used as acid catalyst | WHITBY RESEARCH, Inc. (US) | 1994-02-09 | — | — | EP | disclosed |
| EP-0280703-B1 | COMPOSITIONS COMPRISING 1-ACYL-SUBSTITUTED MORPHOLINES, THIOMORPHOLINES AND PIPERAZINES AND THEIR USES | WHITBY RESEARCH INC (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5073544-A | Penetration promoters | WHITBY, INC. (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0280703-A4 | COMPOSITIONS COMPRISING 1-ACYL-SUBSTITUTED MORPHOLINES, THIOMORPHOLINES AND PIPERAZINES AND THEIR USES. | NELSON RES & DEV COMPANY (US) | 1990-01-08 | — | — | EP | disclosed |
| EP-0280703-A1 | COMPOSITIONS COMPRISING 1-ACYL-SUBSTITUTED MORPHOLINES, THIOMORPHOLINES AND PIPERAZINES AND THEIR USES. | NELSON RES & DEV (US) | 1988-09-07 | — | — | EP | disclosed |
| WO-1988001131-A1 | COMPOSITIONS COMPRISING 1-OXOHYDROCARBYL-SUBSTITUTED AZACYCLOHEXANES AND THEIR USES | NELSON RESEARCH AND DEVELOPMENT COMPANY (US) | 1988-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | GNAI3 2558/4885GNAI1 2786/4885GNAO1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.